

1 **Innate lymphoid cells are activated and their levels correlate with viral load in patients**
2 **with Puumala hantavirus caused hemorrhagic fever with renal syndrome.**

3

4 **Short title:** Innate lymphoid cells in hemorrhagic fever with renal syndrome

5

6 **Author list:** Marina García^a, Anna Carrasco García^a, Johanna Tauriainen^a, Kimia Maleki^a,
7 Antti Vaheri^b, Satu Mäkelä^{d,e}, Jukka Mustonen^{d,e}, Anna Smed-Sörensen^c, Tomas Strandin^{b,c},
8 Jenny Mjösberg^{a#}, Jonas Klingström^{a#}.

9

10 **Affiliations**

11 ^a Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet,
12 Stockholm, Sweden

13 ^b Department of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

14 ^c Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet,
15 Karolinska University Hospital, Stockholm, Sweden.

16 ^d Department of Internal Medicine, Tampere University Hospital, Tampere, Finland

17 ^e Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

18 [#]Equal contribution

19

20 **Corresponding authors.** Dr. Jenny Mjösberg and Dr. Jonas Klingström

21 e-mail: jenny.mjösberg@ki.se

22 e-mail: jonas.klingstrom@ki.se

23

24 **Keywords:** Innate lymphoid cells, NK cells, hantavirus, orthohantavirus, hemorrhagic fever
25 with renal syndrome, viral load

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26

27 **ABSTRACT**

28 **Background.** Innate lymphoid cells (ILCs) are involved in immunity and homeostasis but,
29 except for natural killer (NK) cells, their role in human viral infections is not well known.
30 Puumala virus (PUUV) is a hantavirus that causes the acute zoonotic disease hemorrhagic
31 fever with renal syndrome (HFRS). HFRS is characterized by strong systemic inflammation
32 and NK cells are highly activated in HFRS, suggesting that also other ILCs might be
33 responding to infection.

34 **Methods.** Here we phenotypically analyzed peripheral ILCs in acute and convalescent
35 PUUV-infected HFRS patients. Additionally, plasma levels of soluble factors and viral load
36 were analyzed.

37 **Findings.** Overall, the frequencies of NK cells and naïve ILCs were reduced while the
38 frequency of ILC2, in particular the ILC2-lineage committed c-Kit^{lo} ILC2 subset, was
39 increased during acute HFRS. Interestingly, we observed a negative correlation between viral
40 load and frequencies of both NK and non-NK ILCs in acute HFRS. Phenotypically, ILCs
41 displayed an activated profile with increased proliferation, and showed altered expression of
42 several homing markers during acute HFRS. In line with the observation of activated ILCs,
43 plasma levels of inflammatory proteins, including the ILC-associated cytokines interleukin
44 (IL)-13, IL-23, IL-25, IL-33, and thymic stromal lymphopoietin (TSLP), were elevated during
45 acute HFRS.

46 **Interpretation.** These findings indicate a general involvement of ILCs in response to human
47 hantavirus infection. Further, this constitutes the first comprehensive study of ILCs in a
48 hantavirus-caused disease, aiding in further understanding the role of these cells in disease
49 pathogenesis and in human viral infections in general.

50 **Funding.** A full list of funding bodies that contributed to this study can be found in the
51 Acknowledgements section.

52 **RESEARCH IN CONTEXT**

53 **Evidence before this study**

54 Innate lymphoid cells (ILCs) include a broad range of innate cell subsets involved, among
55 other functions, in early response to infections. Natural killer (NK) cells have been broadly
56 characterized in human viral infections, but much less is known in such context about other
57 more recently discovered ILCs. Puumala virus is one of the causative agents of hemorrhagic
58 fever with renal syndrome (HFRS), an acute zoonotic disease characterized by systemic
59 inflammation. No current treatment or vaccines are available to date for hantavirus-caused
60 diseases and pathogenesis is still not fully understood. A PubMed search up until April 2022
61 using a combination of the terms virus, Puumala virus, hantavirus, HFRS, ILCs, and NK cells
62 shows that while studies have been performed characterizing NK cells in HFRS, no studies
63 are available on the rest of ILCs in hantavirus-caused diseases, which in addition have been
64 studied in only a handful of human viral infections.

65 **Added value of this study**

66 In this study we thoroughly characterized the ILC landscape in circulation and its milieu in
67 acute and convalescent Puumala-infected HFRS patients. We found that the frequency of NK
68 cells and other ILC subsets was altered in the acute HFRS patients as compared to
69 convalescent HFRS patients and control individuals, with a decrease in NK cells and naïve
70 ILCs, and an increase in ILC2. In particular the ILC2-lineage committed c-Kit^{lo} ILC2 subset
71 was found increased. Total ILCs showed increased levels of activation and proliferation, and
72 signs of altered migration patterns in acute HFRS patients. The finding of elevated levels of
73 several soluble inflammatory proteins associated with ILCs in acute HFRS patients further
74 suggests an implication of ILCs in HFRS. Moreover, an association between the frequency of
75 NK cells and non-NK ILCs and plasma viral load suggest a possible connection between
76 viremia and the activity of these cell types during the course of disease.

77 **Implications of all the available evidence**

78 Our research shows that all circulating ILCs, including non-NK ILCs, are activated,
79 proliferating, and correlate with viral load in acute HFRS patients, indicating a general
80 involvement in human hantavirus infection and disease. Being the first comprehensive study
81 on ILCs in hantavirus infections, further research will give relevant insight into the roles of
82 ILCs in disease pathogenesis and protection.

83 INTRODUCTION

84 Innate lymphoid cells (ILCs) are a group of innate immune cells that play important roles in
85 the modulation of immune and inflammatory responses.¹ Naïve ILCs (nILC) constitute an
86 immature subset^{2,3} that can home from peripheral blood to tissues where they give rise to the
87 mature ILC subsets⁴. Mature ILCs are classified in five main subsets based on the
88 transcription factors they express and the cytokines they produce: natural killer (NK) cells,
89 ILC1, ILC2, ILC3, and lymphoid tissue inducer (LTi) cells.^{5,6} NK cells share the same
90 features as ILC1, but in addition can, as opposed to the other ILCs, kill virus-infected cells.⁶
91 ILC1 and ILC3 are mainly found in mucosal tissues while NK cells and ILC2 are found both
92 in tissues and in peripheral blood.^{2,4} Furthermore, two functionally distinct subsets of ILC2
93 can be found in peripheral blood: c-Kit^{lo} and c-Kit^{hi} ILC2, the first being more committed to
94 the ILC2 lineage.⁷

95 NK cells have been extensively described in different viral infections.⁸⁻¹⁰ On the other
96 hand, non-NK ILCs (hereinafter referred to as ILCs) were more recently discovered,^{11,12} and
97 thus less is known regarding their role in viral infections. Due to their location in mucosal
98 tissue, ILCs are on the first line of defense and hence potentially essential in the early phases
99 of viral infections.¹³ Their enrichment in lungs suggests an important role for ILCs in
100 respiratory viral infections.^{13,14} There are conflicting data regarding ILC2 and virus infections:
101 they have been suggested to promote tissue repair and protect the lungs of influenza-infected
102 mice,^{15,16} while other studies reported that ILC2 induce airway hyperreactivity in influenza-
103 infected¹⁷⁻¹⁹ and respiratory syncytial virus-infected²⁰ mice. Furthermore, ILCs have
104 recently been investigated in the context of a few human viral diseases. In HIV-1 infected
105 individuals, levels of ILCs were found to be reduced in ileum and colon,²¹ as well as in
106 circulation, and to negatively correlate with viral load.²² Total peripheral ILC levels were also
107 found to be decreased in SARS-CoV-2-infected coronavirus disease-19 (COVID-19) patients,

108 with ILC2 decreased in severe but not in moderate patients.²³⁻²⁵ Moreover, in infants with
109 respiratory syncytial virus bronchiolitis, elevated levels of ILC2 in the airways were found to
110 associate with disease severity.²⁶ Overall, these studies show an effect of viral infections on
111 the ILC landscape.

112 Hantaviruses (genus *Orthohantavirus*, family *Hantaviridae*, order *Bunyvirales*) are
113 RNA viruses that can cause zoonotic diseases in humans²⁷. The reservoirs of disease-causing
114 hantaviruses are rodents, and humans are normally infected via inhalation of hantavirus-
115 infected rodent excreta.^{28,29} Hantaviruses can cause hemorrhagic fever with renal syndrome
116 (HFRS) in Eurasia and hantavirus pulmonary syndrome (HPS) in the Americas, with up to
117 10% and around 35% case fatality rate, respectively.^{28,30,31} Puumala virus (PUUV) is endemic
118 in Europe, where it is the most common causative agent of HFRS.^{30,32} Hantavirus-infected
119 patients initially develop non-specific symptoms such as high fever and headache, and many
120 eventually present kidney dysfunction (primarily in HFRS), lung dysfunction (primarily in
121 HPS), and gastrointestinal symptoms, including abdominal pain, diarrhea, vomiting, and
122 gastrointestinal bleeding.^{31,33,34} As of today, no specific treatment nor United States Food and
123 Drug Administration / European Medicines Agency-approved vaccines are available for
124 hantavirus-caused diseases.³⁵ Hantaviruses trigger immunopathogenic responses that likely
125 contribute to hyperinflammation³⁶⁻⁴³ and vascular leakage in patients, but the exact
126 mechanisms leading to these events remain to be understood.^{32,44,45} Peripheral NK cells show
127 signs of strong activation and proliferation in the acute phase of HFRS.⁴⁶⁻⁴⁹ B and T cells are
128 highly expanded in the circulation of HFRS and HPS patients, with concomitant elevated
129 levels of CD8⁺ T cells in the respiratory airways,^{36,50-54}. Mucosa-associated invariant T
130 (MAIT) cells were recently shown to be reduced but highly activated in circulation during
131 PUUV-caused HFRS.⁴² Levels of neutrophils are highly increased and also strongly activated
132 in hantavirus-infected patients.⁵⁵⁻⁵⁷ Mononuclear phagocytes are susceptible to infection with

133 hantaviruses, and their activation and redistribution from circulation towards the airways and
134 kidneys in HFRS patients have been reported.^{58–61} Combined, these reports show that
135 hantaviruses trigger strong immune cell responses, indicating a possible involvement of ILCs
136 as well.

137 Here we performed a detailed characterization of peripheral blood ILCs and NK cells,
138 as well as of their cytokine and chemokine milieu, in PUUV-infected HFRS patients. We
139 observed increased plasma levels of inflammatory proteins, including ILC-associated
140 cytokines. We showed that NK cell frequencies are reduced during acute HFRS but recover
141 during convalescence. While total ILC frequencies did not change, we report increased
142 frequency of ILC2 and a concomitant decreased frequency of nILC during acute HFRS. In
143 particular, the ILC2-lineage committed c-Kit^{lo} ILC2 subset was increased during acute HFRS.
144 Furthermore, NK cells and ILCs displayed an activated phenotype and ongoing proliferation
145 during acute HFRS. Interestingly, we observed a negative correlation between viral load and
146 the frequencies of both NK cells and ILCs in acute HFRS, suggesting a potential direct or
147 indirect influence of hantaviruses on the ILC landscape in HFRS patients.

148

149 **MATERIAL AND METHODS**

150 **Patient samples**

151 17 patients with serologically confirmed acute HFRS were included in the study. The patients
152 were diagnosed with PUUV infection at the Tampere University Hospital, Finland during
153 2002–2007. Whole blood samples were collected, and peripheral blood mononuclear cells
154 (PBMCs) were isolated as previously described and stored in liquid nitrogen at -150°C, while
155 plasma was stored at -80°C, until further use.⁶¹

156 The study was approved by the Ethics Committee of Tampere University Hospital
157 (ethical permit nr. R04180) and all subjects gave written informed consent. The samples were

158 collected in the acute phase of disease (5-8 days after onset of symptoms), during the early
159 convalescence phase (20-27 days after onset of symptoms), and at a late convalescence phase
160 at 180 or 360 days after onset of symptoms. Patients were stratified as having either mild or
161 severe HFRS based on a scoring system adapted from the sequential organ failure assessment
162 scoring system, where the maximum levels of creatinine (4 = > 440, 3 = 300-440, 2 = 171-
163 299, 1 = 110-170, and 0 = < 110 $\mu\text{mol/l}$), minimum level of platelets (4 = < 20, 3 = 20-49, 2 =
164 50-99, 1 = 100-150, and 0 = > 150 $\times 10^3/\mu\text{l}$), and minimum mean arterial blood pressure (1 =
165 < 70 and 0 = ≥ 70 mmHg) were ranked. A total score of ≥ 5 was considered severe and < 5
166 mild.^{61,62}

167 As controls, PBMCs were obtained from buffy coats from 10 healthy blood donors
168 from the Blood Transfusion Clinic at the Karolinska University Hospital Huddinge,
169 Stockholm, Sweden (ethical permit nr. 2020-02604) and stored in liquid nitrogen until further
170 use. PBMCs were isolated from the buffy coats by density centrifugation using Lymphoprep
171 (StemCell Technologies), according to manufacturer's guidelines.

172

173 **Viral load in plasma**

174 RNA was isolated from 140 μl of patient EDTA-plasma using column-based RNA isolation
175 kit following the manufacturer's instructions (Viral RNA mini kit, Qiagen). Isolated RNA
176 was subjected to PUUV S RNA RT-qPCR analysis based on a previously described
177 protocol,⁶³ with TaqMan fast virus 1-step master mix (Thermo Scientific) using AriaMx
178 instrumentation (Agilent).

179

180 **Flow cytometry analysis**

181 PBMC samples were thawed in RPMI (Cytiva) complete media [L-glutamine (ThermoFisher
182 Scientific), FCS (Sigma-Aldrich), penicillin/streptomycin (Cytiva)] with DNase (Roche) and

183 counted. 3-4 million cells per sample were stained. Briefly, cells were incubated with
184 LIVE/DEAD Fixable Green Dead Cell Stain Kit (ThermoFischer Scientific) -used as a
185 viability marker- and fluorochrome-conjugated antibodies directed against surface markers
186 (**Suppl Table 1**) for 20 min at room temperature in the dark followed by 2 washes with flow
187 cytometry buffer (2 mM EDTA in PBS). Cells were then fixed and permeabilized using
188 FACS Lysing solution and FACS Permeabilizing solution (BD Biosciences), and next
189 incubated with intracellular staining antibodies (**Suppl Table 1**) for 30 min at 4°C in the dark.
190 Cells were then washed and resuspended in flow cytometry buffer. Samples were acquired
191 with a BD LSR Fortessa (BD Biosciences) flow cytometer. Flow cytometric analysis was
192 performed using FlowJo version 10.7.2 (TreeStar, Ashland). To ensure unbiased manual
193 gating, a blinded analysis was implemented, whereby all FCS3.0 files were renamed and
194 coded by one person and blindly analyzed by another person. All samples were compensated
195 electronically, and gatings were based on fluorescent-minus-one (FMO) or negative controls.
196 After all gatings were performed, samples were decoded and data analysis was performed.

197 ILCs were defined as live (DCM⁻) CD1a⁻ CD14⁻ CD19⁻ CD34⁻ CD123⁻ BDCA2⁻ FcεR⁻
198 TCRα/β⁻ TCRγδ⁻ CD3⁻ CD45⁺ CD127^{hi}. NK cells were defined as DCM⁻ CD1a⁻ CD14⁻ CD19⁻
199 CD34⁻ CD123⁻ BDCA2⁻ FcεR⁻ TCRα/β⁻ TCRγδ⁻ CD3⁻ CD45⁺ CD56⁺ CD127^{lo/hi}. For a detailed
200 gating strategy see **Suppl Fig 1**.

201

202 **Multiplex immunoassay**

203 Plasma levels of IL-5, IL-6, IL-7, IL-10, IL-13, IL-15, IL-17A, IL-18, IL-23, IL- 25, IL-33,
204 IFN-γ, TNF, CCL20, CCL27, CCL28, GM-CSF, TSLP, and granzyme A were measured in
205 plasma diluted 1:2, using a custom made Magnetic Luminex Screening assay (R&D Systems,
206 Minneapolis) and analysed in a Magpix instrument (Luminex), according to manufacturer's
207 guidelines. For graphing purposes, values not calculated by the instrument's software -

208 because they were out of range in the lower standard range- were replaced by half of the value
209 of the lowest detectable value for the given soluble factor measured.

210

211 **Statistical analysis**

212 Statistical analyses were performed using GraphPad Prism software v.9.2 for MacOSX
213 (GraphPad Software). Statistical differences between healthy controls and HFRS patients
214 were analyzed with Kruskal-Wallis test followed by Dunn's multiple comparison post hoc
215 test. Paired comparisons between HFRS in the different disease stages (acute, early
216 convalescence, and late convalescence) were performed using Wilcoxon test. p-values < 0.05
217 were considered statistically significant. Spearman's rank correlation coefficient was used for
218 assessing correlations. Spearman's correlation matrixes were generated with R (v.4.1.1; R
219 Core Team, 2020) using package corrplot (v.0.9). Principal component analysis (PCA) was
220 performed in R (v.4.1.1) using packages Factoextra (v.1.0.7), FactoMineR (v.2.4),
221 RColorBrewer (v.1.1-2), and ggplot2 (v.3.3.5). Data was normalised in R using the scale
222 argument within the PCA function. Where data was missing, the values were imputed using
223 package missMDA (v.1.18).

224

225 **Role of the funding sources**

226 The funders of this study had no role in the study design, data collection, data analysis, data
227 interpretation, or writing of the report.

228

229 **RESULTS**

230 **Study design and patient characteristics**

231 A total of 17 PUUV-infected hospitalized HFRS patients and 10 healthy controls were
232 included in the study (**Table 1**). Peripheral blood samples were obtained at the acute (5-8 days

233 after onset of symptoms), early convalescent (20-27 days after onset of symptoms), and late
234 convalescent (180 or 360 days after onset of symptoms) phase of disease (**Fig 1a**).
235 Hospitalized HFRS patients showed a typical clinical presentation during the acute phase,
236 with thrombocytopenia, elevated C-reactive protein (CRP) and creatinine plasma levels, and
237 viral load (**Table 1, Fig 1b, and Suppl Table 2**). For most of the patients all parameters
238 normalized to levels within the normal range during the convalescent phase of disease (**Fig**
239 **1b**). The severity of the patients was assessed with a scoring system based on platelet counts,
240 creatinine values, and mean arterial blood pressure values, as previously describe.^{61,62} Two
241 patients scored as severe, while all other scored as mild (**Suppl Table 2**).

242

243 **HFRS patients present a strong inflammatory response during the acute phase of** 244 **disease**

245 Hantavirus disease is characterized by strong systemic inflammatory responses.^{37,40–43,64–67}
246 Using a multiplex immunoassay, we assessed the plasma levels of 19 cytokines in HFRS
247 patients during the acute and convalescent phase of disease. Except for interleukin (IL)-5, IL-
248 7, and IL-17A (**Suppl Fig 1a**), we observed differences in levels of all proteins between acute
249 and later stages of HFRS (**Fig 2a and b**). As previously reported,^{37,40–43,64–67} the plasma levels
250 of tumor necrosis factor (TNF), IL-6, granulocyte-macrophage colony-stimulating factor
251 (GM-CSF), IL-10, interferon gamma (IFN- γ), IL-15, IL-18, and granzyme A (GrzA) were all
252 significantly higher in acute HFRS as compared to the convalescent phases (**Fig 2b**). Further,
253 we observed significantly higher levels of the type 2-associated cytokines IL-13, IL-25 (also
254 called IL-17E), IL-33, and thymic stromal lymphopoietin (TSLP), related to ILC2 and T
255 helper 2 cell activity and involved in functions such as tissue repair.^{68,69} We also observed
256 significantly higher levels of the type 3-associated cytokine IL-23 in the acute phase of
257 HFRS, involved in the activation of immune cells such as ILC3 and T helper 17 cells which

258 have a role in protection from tissue damage (**Fig 2b**).^{5,70} Moreover, we observed that levels
259 of the chemokines CCL20 and CCL27 were significantly higher in acute samples, while the
260 level of CCL28 was significantly decreased (**Fig 2b**).

261 Principal component analysis (PCA) showed that samples from the acute phase
262 separated from samples from the early and late convalescent phase. This separation was
263 mainly driven by IL-10, GrzA, IFN- γ , TNF, IL-18, CCL27 and IL-33 (**Fig 2c**). Interestingly,
264 patient 3, one of the two most severely ill patients in the cohort, deviated from the rest of the
265 patients, both in the acute and early convalescent phase (**Fig 2c**). This patient showed the
266 highest levels of several soluble factors and presented higher levels of many of them in the
267 early convalescent phase than in the acute phase (**Fig 2a**), suggesting a longer than usual
268 acute phase.

269 Additionally, we observed significant positive correlations between the type 2-
270 associated cytokines IL-25 and IL-13 and between IL-25 and TSLP during the acute phase of
271 HFRS (**Suppl Fig 1b** and **Fig 2d and e**). Further, out of the 15 acute HFRS patients, 13 were
272 positive for PUUV S RNA in blood and a positive correlation was seen as well between viral
273 load and IFN- γ (**Suppl Fig 1b** and **Fig 2f**).

274 Altogether, these results showed that PUUV-infected HFRS patients display a strong
275 inflammatory response, including elevated levels of 16 cytokines many of which are known to
276 be produced by or involved in the activation of ILCs and NK cells.

277

278 **Peripheral NK cells are activated but decreased in frequency during acute HFRS**

279 We next characterized the ILC and NK cell compartments in PBMCs from HFRS patients.
280 For the identification and analysis of ILCs and NK cells, we used 18-parameter flow
281 cytometry and a modification of a well-established gating strategy (**Suppl Fig 2**).⁷¹

282 We observed decreased frequencies of total CD56⁺ NK cells in peripheral blood in the
283 acute and early convalescent phase of disease, which normalized in late convalescence (**Fig**
284 **3a**). There was a decreased frequency of CD56^{dim} NK cells, with a concomitant increase of
285 the smaller population of CD56^{bright} NK cells, during the acute phase of HFRS (**Fig 3b and c**).
286 High frequencies of CD69⁺ and HLA-DR⁺ total CD56⁺ NK cells were detected in the acute
287 phase of HFRS, indicating NK cell activation (**Fig 3d**). As expected from the general NK cell
288 activation, frequencies of NKp44⁺ and NKG2A⁺ NK cells were also increased in the acute
289 phase of HFRS (**Fig 3d**). Furthermore, the frequency of Ki-67⁺ NK cells was increased,
290 showing that the NK cells proliferated during acute HFRS (**Fig 3d**). Additionally, when
291 analyzing for homing receptors, we observed a decreased frequency of $\alpha 4\beta 7$ ⁺ NK cells and an
292 increased frequency of CCR6⁺ and CCR10⁺ NK cells in the acute phase of HFRS (**Fig 3d**),
293 suggesting an effect on NK cell migration. The frequency of CD45RA⁺ and CD161⁺ NK cells
294 was decreased in HFRS patients as compared to healthy controls, with a tendency to recovery
295 in the convalescent phase of HFRS (**Fig 3d**). Analysis of surface markers in the CD56^{bright} and
296 CD56^{dim} NK cell subsets showed similar results as observed for total NK cells (**Suppl Fig 3**).
297 A PCA revealed a separation of acute HFRS from convalescent HFRS patients and healthy
298 controls based on the level of expression of the different analyzed surface markers in total NK
299 cells (**Fig 3e**).

300 Next, we examined correlations between frequencies of NK cells and both soluble
301 plasma proteins and clinical parameters (**Suppl Fig 4a-d**). IL-10 plasma levels positively
302 correlated with the frequencies of both activated (CD69⁺) and proliferating (Ki-67⁺) NK cells
303 (**Fig 3f and g**). Granzyme A levels correlated positively with the frequency of CD69⁺ NK
304 cells (**Fig 3h**), and negatively with the frequency of CD161⁺ NK cells (**Fig 3i**). Interestingly,
305 the frequency of activated (CD69⁺) NK cells correlated positively with viral load while the

306 frequency of total NK cells showed a negative correlation with viral load during the acute
307 phase of HFRS (**Fig 3j and k**).

308

309 **Peripheral ILCs are activated and proliferate during acute HFRS**

310 We next characterized the peripheral ILC responses in the HFRS patients. No significant
311 difference in total ILC frequency was observed between the patients and the healthy controls
312 (**Fig 4a**). Interestingly, as for NK cells, we observed a negative correlation between viral load
313 and the frequency of ILCs in acute HFRS, showing reduced frequencies of peripheral ILCs in
314 patients with higher viral loads (**Fig 4b**). Furthermore, we observed increased frequencies of
315 activated (CD69⁺) and proliferating (Ki-67⁺) ILCs during the acute phase of HFRS (**Suppl**
316 **Fig 5a**), while no differences were observed in the frequencies of NKp44, HLA-DR, and
317 CD45RA-expressing ILCs (**Suppl Fig 5a**). When assessing expression of homing markers,
318 we found a decreased frequency of $\alpha 4\beta 7^+$ ILCs in acute HFRS, but no significant difference
319 in frequencies of ILCs expressing the chemokine receptors CCR6 and CCR10 (**Suppl Fig 5a**).

320 Next, we explored specific ILC subsets. CD117^{neg} ILCs in peripheral blood have been
321 shown to make up a heterogenous population with yet undefined functions.² We therefore
322 decided to focus our analysis on the more well-defined nILC and ILC2. The composition of
323 these ILC subsets changed over time in the HFRS patients (**Fig 4c**). We observed an increase
324 in ILC2 frequency and a decreased frequency of naïve ILC (nILC) in the acute phase of
325 HFRS (**Fig 4c and d**).

326

327 **Peripheral c-Kit^{lo} ILC2 are increased in frequency during HFRS**

328 Next, we characterized the phenotype of the ILC subsets. Increased frequencies of activated
329 (CD69⁺) and proliferating (Ki-67⁺) nILC were observed in acute HFRS (**Fig 4e**). Moreover,
330 similar to NK cells (**Fig 3d**), a decreased frequency of $\alpha 4\beta 7^+$ nILC was observed in acute

331 HFRS (**Fig 4e**). No differences were observed in the frequencies of nILCs expressing HLA-
332 DR, NKp44, CCR6, and CCR10 in HFRS patients as compared to healthy controls (**Fig 4e**).
333 PCA based on the frequency of expression of surface markers in nILC showed a separation
334 between the acute HFRS patients and healthy controls (**Fig 4f**).

335 The ILC2 population showed a similar phenotypic pattern as the nILC, with increased
336 frequency of activated (CD69⁺) and proliferating (Ki-67⁺) cells during acute HFRS (**Fig 4g**).
337 Additionally, a significantly decreased frequency of CCR6⁺ ILC2 was observed in the acute
338 phase of disease (**Fig 4g**), while no differences were observed in the frequencies of ILC2
339 expressing NKp44, HLA-DR, CCR10, and $\alpha 4\beta 7$ in HFRS as compared to healthy controls
340 (**Fig 4g**). In line with these findings, a PCA based on the frequency of expression of surface
341 markers on ILC2s showed no clear separation between the acute and convalescent HFRS, but
342 a separation of the acute and control samples was observed (**Fig 4h**). Further, when analyzing
343 for possible correlations to soluble proteins (**Suppl Fig 6**), we observed a positive correlation
344 between the plasma levels of IL-10 and the frequency of CD69⁺ ILC2 (**Fig 4i**) and between
345 plasma levels of the CCR10 ligand CCL27 and CCR10⁺ ILC2 (**Fig 4j**), as well as a negative
346 correlation between plasma levels of TSLP and frequency of CCR10⁺ ILC2 in acute HFRS
347 patients (**Fig 4k**). The first two correlations were also observed for total ILCs, as well as a
348 positive correlation between plasma levels of IL-7 and Ki-67⁺ ILC (**Suppl Fig 5b**).

349 Having observed an increased frequency of ILC2 (**Fig 4d**), a decreased frequency of
350 CCR6⁺ ILC2 (**Fig 4g**), and increased plasma levels of type 2 cytokines in acute HFRS (**Fig 2**),
351 we next assessed whether there were changes in the ILC2 subsets in HFRS patients. Indeed,
352 we observed increased frequencies of c-Kit^{lo} ILC2 and, concomitantly, decreased frequencies
353 of c-Kit^{hi} ILC2 during the acute phase of HFRS, as compared to convalescent HFRS patients
354 and healthy controls (**Fig 5a and b**). Moreover, c-Kit^{hi} ILC2 showed higher frequency of
355 CCR6 expression than c-Kit^{lo} ILC2 both in patients and healthy controls (**Fig 5c**) and,

356 aligning with the relative depletion of CCR6⁺ ILC2 in acute HFRS, (**Fig 4g**) we observed a
357 lower frequency of CCR6⁺ c-Kit^{hi} ILC2 in the acute phase of HFRS as compared to the
358 convalescent phase (**Fig 5c**).

359

360 **DISCUSSION**

361 Here we provide a detailed characterization of total ILCs, including both NK cells and non-
362 NK ILCs, in blood samples from PUUV-infected HFRS patients. We reveal that total ILCs
363 are activated and show an altered composition correlating to viral load.

364 Whereas NK cells have been extensively described in several human viral infections⁸⁻
365¹⁰ including hantavirus infections,^{46-49,72,73} ILCs remain understudied in human viral
366 infections. Recent studies reveal dysregulated frequencies and phenotypes of ILCs in HIV-
367 1,^{21,22} SARS-CoV2,²³⁻²⁵ rhinovirus,⁷⁴ and respiratory syncytial virus (RSV) infection.²⁶ Here
368 we characterized ILCs and NK cell responses in the context of human hantavirus infection.

369 HFRS is characterized by a strong general immune activation, including
370 hyperinflammation.^{30,75} Some typical laboratory features are leukocytosis, thrombocytopenia,
371 high CRP and hematocrit levels, and due to acute kidney injury, increased serum creatinine,
372 proteinuria, and haematuria.^{28,31,76-78} Viral load peaks between the first 3 to 5 days during the
373 febrile phase of disease, and viral load is normally not detectable in the convalescent phase of
374 disease^{31,32,79,80}. In line with this, the HFRS patients in our study presented with typical
375 laboratory findings together with a strong inflammatory response in the acute phase of
376 disease.^{37,40-43,64-67} We observed an increase of several type 2-associated cytokines such as
377 IL-13, IL-25, IL-33, and TSLP in acute PUUV-infected HFRS patients. The alarmins IL-25,
378 IL-33, and TSLP are known activators of ILC2, which upon activation can secrete IL-13.^{15,81}
379 These alarmins are upregulated upon infection or damage mainly of epithelial, endothelial,
380 and stromal cells.⁸²⁻⁸⁴ Given that the main target cell of hantaviruses are endothelial cells,³⁰ it

381 is likely that hantavirus induce the secretion of the mentioned alarmins by these cells in HFRS
382 patients. Interestingly, IL-33 has previously been found to be also elevated in plasma of
383 Hantaan virus-infected HFRS patients and to positively correlate with disease severity.⁸⁵

384 As recently shown by Resman Rus and colleagues,⁴⁸ we observed transiently reduced
385 NK cell frequencies in peripheral blood of PUUV-infected HFRS patients, returning to
386 normal levels during convalescence. Moreover, as earlier shown,⁴⁷ we observed that
387 remaining circulatory NK cells were highly proliferating, with approximately half of them
388 expressing Ki-67. During the acute phase of HFRS, NK cells also showed increased
389 expression of several activation markers and altered expression of chemokine receptors
390 associated with migration to tissues, such as lung (CCR6) and intestine ($\alpha 4\beta 7$).⁸⁶⁻⁸⁹ This
391 suggests migration of NK cells to tissues, which could be the cause of the observed decreased
392 frequencies of NK cells in peripheral blood during acute HFRS. Interestingly, viral load
393 correlated negatively with the frequency of NK cells in peripheral blood but positively with
394 the frequency of activated NK cells, suggesting that active viral replication impacts, in an
395 unknown manner, the activation of NK cells during HFRS. We have previously shown that
396 hantaviruses have strong anti-apoptotic properties that potentially protect infected cells from
397 cytotoxic lymphocyte mediated killing and may trigger NK cell mediated bystander killing of
398 uninfected cells.^{72,73,90,91} Whether this holds true *in vivo* remains to be investigated, but the
399 strong activation of NK cells we observe in HFRS patients could be a sign of continuous
400 attempts of NK cells to kill hantavirus-infected cells. Of further interest, we observed that
401 levels of IFN- γ also positively correlated with viral load in HFRS patients. IFN- γ is a cytokine
402 with strong antiviral effects produced by a wide array of innate and adaptive lymphocytes,
403 including ILCs, NK cells, NKT cells, and T cells.⁹²⁻⁹⁵ The main targets of hantavirus
404 infection, such as endothelial cells and monocytes,^{30,59} are not known to express IFN- γ , so this

405 correlation further suggests that active viral replication in infected cells indirectly leads to
406 enhanced IFN- γ production by immune cells, such as activated NK cells.

407 We observed a decreased frequency of CD161⁺ NK cells in acute HFRS patients. The
408 role of CD161 in NK cells is not fully understood, but it has been suggested to mark pro-
409 inflammatory NK cells with a high ability to respond to innate cytokines.⁹⁶ There are previous
410 reports of modulation of CD161 expression in NK cells in other viral infections, such as a
411 reduced CD161 expression in NK cells in acute hepatitis C virus infection which associated
412 with enhanced viral clearance,⁹⁷ reduced frequency of CD161⁺ NK cells in Chikungunya-
413 infected patients,⁹⁸ and depletion of CD161⁺ NK cells in cytomegalovirus infection.⁹⁶
414 Paralleling the findings on NK cells, downregulation of CD161 expression on MAIT cells has
415 been described in HFRS,⁴² as well as in HIV-infected individuals.⁹⁹ Interestingly, we also
416 observed a negative correlation between the plasma levels of granzyme A and the frequency
417 of CD161⁺ NK cells in acute HFRS. Even though NK cells are not the sole source of
418 granzyme A in plasma, this observation could suggest that the decrease in frequency of
419 CD161⁺ NK cells - and thus increase of a CD161⁻ NK population - is related to higher NK
420 cell degranulation and cytotoxicity for viral control in HFRS patients. Along this line, we also
421 observed a positive correlation between activated NK cells and the levels of IL-10, a cytokine
422 that has been reported to enhance the effector functions of NK cells.¹⁰⁰

423 The frequency of ILCs is reduced in the circulation of acute HIV-infected individuals,
424 and correlates negatively with viral load.²² In COVID-19 we also recently reported a decrease
425 in peripheral ILC frequencies and numbers.²³ In contrast, here we did not observe a
426 significant change in the frequency of ILCs in HFRS as compared to healthy controls.
427 Interestingly though, and in line with the previous report for HIV infection,²² frequencies of
428 peripheral ILCs in acute HFRS showed a strong negative correlation with viral load.
429 Furthermore, as described for moderate COVID-19 patients,²³ acute HFRS patients presented

430 increased frequencies of ILC2 with a concomitant reduction of nILC frequencies. In contrast
431 to our findings in COVID-19 patients,²³ we observed increased frequencies of Ki-67-
432 expressing ILC2 and nILC in HFRS patients. Moreover, the decreased levels of $\alpha 4\beta 7^+$ nILCs
433 in acute HFRS suggest that the reduced frequency of peripheral blood nILCs could be due to
434 their migration to tissues ⁴. Alternatively, nILC might differentiate into mature ILC subsets,
435 such as ILC2s, in the circulation. Of interest, acute HFRS patients presented increased
436 frequencies of c-Kit^{lo} ILC2. Two ILC2 subsets have been defined, differing in their surface
437 expression of c-Kit and their functionality. c-Kit^{lo} ILC2 are more mature and ILC2-lineage
438 committed, while c-Kit^{hi} ILC2 show plasticity towards an ILC3 phenotype and functionality.⁷
439 Moreover, c-Kit^{lo} ILC2 express less CCR6 compared to c-Kit^{hi} ILC2.⁷ In line with this, acute
440 HFRS patients showed decreased frequency of CCR6⁺ c-Kit^{hi} ILC2 as compared to
441 convalescent patients and healthy controls. This suggests a skewing of c-Kit^{hi} ILC2 towards
442 more ILC2-committed cells in HFRS, possibly explaining the increase in c-Kit^{lo} ILC2
443 frequencies in acute HFRS. Alternatively, this decrease in CCR6⁺ c-Kit^{hi} ILC2 levels could
444 also be due to migration of these cells to lungs, where ILC2 have been shown to play an
445 important role in lung tissue repair during influenza infection in mice.^{15,16}

446 Here we have characterized peripheral ILCs in PUUV-infected HFRS patients. Future
447 characterization of ILCs in tissue samples, such as lung and intestines, can add important
448 knowledge regarding circulating ILC infiltration and local ILC responses.

449 In conclusion, this study provides the first comprehensive characterization of total
450 circulating ILCs in hantavirus-infected patients. We report an overall activated and
451 proliferating ILC profile in these patients, with a particular increased frequency of the ILC2
452 subset, and a skewing towards the ILC2-lineage committed c-Kit^{lo} ILC2 in acute HRFS.
453 Additionally, we show that NK cells are reduced in frequencies and confirm that remaining
454 circulating NK cells are highly activated and proliferating in acute HFRS. Moreover, we

455 report a negative correlation between viral load and the frequencies of both NK cells and
456 ILCs in acute HFRS, suggesting a potential influence of viral replication on these cells during
457 the acute phase of hantavirus-caused disease.

458

459 **CONTRIBUTORS**

460 All authors read and approved the final version of the manuscript.

461 MG: data curation, funding acquisition, formal analysis, investigation, methodology,
462 visualization, writing-original draft, writing-review & editing;

463 ACG: data curation, formal analysis, investigation, methodology, visualization, writing-
464 review & editing;

465 JT: methodology;

466 KM: methodology;

467 AV: resources, funding acquisition;

468 SM: resources, funding acquisition;

469 JuM: resources, funding acquisition;

470 ASS: resources;

471 TS: resources; funding acquisition;

472 JeM: conceptualization, investigation, visualization, writing-review & editing, supervision;

473 JK: conceptualization, funding acquisition, investigation, visualization, writing-review &
474 editing, supervision.

475

476 **DECLARATION OF INTERESTS**

477 The authors have no competing financial interests or conflicts.

478

479

480 **ACKNOWLEDGMENTS**

481 We thank the patients and volunteers who have contributed with clinical material to this
482 study. We also thank Ms. Sanna Mäki for expert technical assistance. This study was
483 supported by grants from the Swedish Research Council (projects K2015-56X- 22774-01-3
484 and 2018-02646 to JK), Karolinska Institutet Research Foundation (project 2020-01469 to
485 MG), the Academy of Finland (project 321809 to TS), Magnus Ehrnrooth Foundation (to
486 AV), and Sigrid Jusélius Foundation (to AV and JuM), and the Competitive State Research
487 Financing of the Responsibility Area of Tampere University Hospital (9AA050 and 9AB046
488 to JuM and 9AA052 to SM).

489

490 **DATA SHARING STATEMENT**

491 The authors declare that the data supporting the findings of this study are available from the
492 corresponding authors upon reasonable request.

493

494 **REFERENCES**

- 495 1. Sonnenberg GF, Hepworth MR. Functional interactions between innate lymphoid cells
496 and adaptive immunity. *Nat Rev Immunol* 2019; **19**: 599–613. doi:10.1038/s41577-
497 019-0194-8
- 498 2. Mazzurana L, Czarnewski P, Jonsson V, Wigge L, Ringnér M, Williams TC, et al.
499 Tissue-specific transcriptional imprinting and heterogeneity in human innate lymphoid
500 cells revealed by full-length single-cell RNA-sequencing. *Cell Res* 2021; **31**: 554–68.
501 doi:10.1038/s41422-020-00445-x
- 502 3. Kokkinou E, Pandey RV, Mazzurana L, Gutierrez-Perez I, Tibbitt CA, Weigel W, et al.
503 CD45RA + CD62L – ILCs in human tissues represent a quiescent local reservoir for
504 the generation of differentiated ILCs. *Sci Immunol* 2022; **7**: eabj8301.

- 505 doi:10.1126/sciimmunol.abj8301
- 506 4. Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge A, et al. Systemic
507 Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation. *Cell* 2017;
508 **168**: 1086–100. doi:10.1016/j.cell.2017.02.021
- 509 5. Vivier E, Artis D, Colonna M, Dieffenbach A, Di Santo JP, Eberl G, et al. Innate
510 Lymphoid Cells: 10 Years On. *Cell* 2018; **174**: 1054–66.
511 doi:10.1016/j.cell.2018.07.017
- 512 6. Spits H, Artis D, Colonna M, Dieffenbach A, Di Santo JP, Eberl G, et al. Innate
513 lymphoid cells—a proposal for uniform nomenclature. *Nat Rev Immunol* 2013; **13**: 145–
514 9. doi:10.1038/nri3365
- 515 7. Hochdörfer T, Winkler C, Pardali K, Mjösberg J. Expression of c-Kit discriminates
516 between two functionally distinct subsets of human type 2 innate lymphoid cells. *Eur J*
517 *Immunol* 2019; **49**: 884–93. doi:10.1002/eji.201848006
- 518 8. Jost S, Altfeld M. Control of human viral infections by natural killer cells. *Annu Rev*
519 *Immunol* 2013; **31**: 163–94. doi:10.1146/annurev-immunol-032712-100001
- 520 9. Brandstadter JD, Yang Y. Natural killer cell responses to viral infection. *J Innate*
521 *Immun* 2011; **3**: 274–9. doi:10.1159/000324176
- 522 10. Lam VC, Lanier LL. NK cells in host responses to viral infections. *Curr Opin Immunol*
523 2017; **44**: 43–51. doi:10.1016/j.coi.2016.11.003.
- 524 11. Mebius RE, Rennert P, Weissman IL. Developing lymph nodes collect CD4+CD3-
525 LTβ+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B
526 cells. *Immunity* 1997; **7**: 493–504. doi:10.1016/S1074-7613(00)80371-4
- 527 12. Spits H, Di Santo JP. The expanding family of innate lymphoid cells: Regulators and
528 effectors of immunity and tissue remodeling. *Nat Immunol* 2011; **12**: 21–7.
529 doi:10.1038/ni.1962

- 530 13. Hildreth AD, O'sullivan TE. Tissue-resident innate and innate-like lymphocyte
531 responses to viral infection. *Viruses* 2019; **11**. doi:10.3390/v11030272
- 532 14. Stehle C, Hernández DC, Romagnani C. Innate lymphoid cells in lung infection and
533 immunity. *Immunol Rev* 2018; **286**: 102–19. doi:10.1111/imr.12712
- 534 15. Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CGK, Doering TA, et al.
535 Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza
536 virus. *Nat Immunol* 2011; **12**: 1045–54. doi:10.1038/ni.2131
- 537 16. Califano D, Furuya Y, Roberts S, Avram D, McKenzie ANJ, Metzger DW. IFN- γ
538 increases susceptibility to influenza A infection through suppression of group II innate
539 lymphoid cells. *Mucosal Immunol* 2018; **11**: 209–19. doi:10.1038/mi.2017.41
- 540 17. Chang YJ, Kim HY, Albacker LA, Baumgarth N, McKenzie ANJ, Smith DE, et al.
541 Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently
542 of adaptive immunity. *Nat Immunol* 2011; **12**: 631–8. doi:10.1038/ni.2045
- 543 18. Shim DH, Park YA, Kim MJ, Hong JY, Baek JY, Kim KW, et al. Pandemic influenza
544 virus, pH1N1, induces asthmatic symptoms via activation of innate lymphoid cells.
545 *Pediatr Allergy Immunol* 2015; **26**: 780–8. doi:10.1111/pai.12462
- 546 19. Li BWS, de Bruijn MJW, Lukkes M, van Nimwegen M, Bergen IM, KleinJan A, et al.
547 T cells and ILC2s are major effector cells in influenza-induced exacerbation of allergic
548 airway inflammation in mice. *Eur J Immunol* 2019; **49**: 144–56.
549 doi:10.1002/eji.201747421
- 550 20. Stier MT, Bloodworth MH, Toki S, Newcomb DC, Goleniewska K, Boyd KL, et al.
551 Respiratory syncytial virus infection activates IL-13–producing group 2 innate
552 lymphoid cells through thymic stromal lymphopoietin. *J Allergy Clin Immunol* 2016;
553 **138**: 814-824.e11. doi:10.1016/j.jaci.2016.01.050
- 554 21. Krämer B, Goeser F, Lutz P, Glässner A, Boesecke C, Schwarze-Zander C, et al.

- 555 Compartment-specific distribution of human intestinal innate lymphoid cells is altered
556 in HIV patients under effective therapy. *PLoS Pathog* 2017; **13**.
557 doi:10.1371/journal.ppat.1006373
- 558 22. Kløverpris HN, Kazer SW, Mjösberg J, Mabuka JM, Wellmann A, Ndhlovu Z, et al.
559 Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-Infection in the
560 Absence of Viral Suppression. *Immunity* 2016; **44**: 391–405.
561 doi:10.1016/j.immuni.2016.01.006
- 562 23. García M, Kokkinou E, Carrasco García A, Parrot T, Palma Medina LM, Maleki KT, et
563 al. Innate lymphoid cell composition associates with COVID-19 disease severity. *Clin
564 Transl Immunol* 2020; **9**: e1224. doi:10.1002/cti2.1224
- 565 24. Gomez-Cadena A, Spehner L, Kroemer M, Khelil M Ben, Bouiller K, Verdeil G, et al.
566 Severe COVID-19 patients exhibit an ILC2 NKG2D+ population in their impaired ILC
567 compartment. *Cell Mol Immunol* 2021; **18**: 484–6. doi:10.1038/s41423-020-00596-2
- 568 25. Gomes AM, Farias GB, Dias-Silva M, Laia J, Trombetta AC, Godinho-Santos A, et al.
569 SARS-CoV2 pneumonia recovery is linked to expansion of Innate Lymphoid Cells
570 type 2 expressing CCR10. *Eur J Immunol* 2021; **0**: 1–8. doi:10.1002/eji.202149311
- 571 26. Vu LD, Siefker D, Jones TL, You D, Taylor R, DeVincenzo J, et al. Elevated levels of
572 type 2 respiratory innate lymphoid cells in human infants with severe respiratory
573 syncytial virus bronchiolitis. *Am J Respir Crit Care Med* 2019; **200**: 1414–23.
574 doi:10.1164/rccm.201812-2366OC
- 575 27. Kuhn JH, Adkins S, Agwanda BR, Al Kubrusli R, Alkhovsky S V., Amarasinghe GK,
576 et al. 2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae),
577 including the large orders Bunyavirales and Mononegavirales. *Arch Virol* 2021; **166**:
578 3513–66. doi:10.1007/s00705-021-05143-6
- 579 28. Jonsson CB, Figueiredo LTM, Vapalahti O. A global perspective on hantavirus

- 580 ecology, epidemiology, and disease. *Clin Microbiol Rev* 2010; **23**: 412–41.
- 581 29. Sabino-Santos Jr G, Gonçalves F, Martins RB, Gagliardi TB, Souza WM De, Muylaert
582 RL, et al. Natural infection of Neotropical bats with hantavirus in Brazil. *Sci Rep* 2018;
583 **8**: 1–8. doi:10.1038/s41598-018-27442-w
- 584 30. Vaheri A, Strandin T, Hepojoki J, Sironen T, Henttonen H, Mäkelä S, et al.
585 Uncovering the mysteries of hantavirus infections. *Nat Rev Microbiol* 2013; **11**: 539–
586 50. doi:10.1038/nrmicro3066
- 587 31. Avšič-Županc T, Saksida A, Korva M. Hantavirus infections. *Clin Microbiol Infect*
588 2019; **21**: e6–16. doi:10.1111/1469-0691.12291
- 589 32. Klingström J, Smed-Sörensen A, Maleki KT, Solà-Riera C, Ahlm C, Björkström NK,
590 et al. Innate and adaptive immune responses against human Puumala virus infection:
591 immunopathogenesis and suggestions for novel treatment strategies for severe
592 hantavirus-associated syndromes. *J Intern Med* 2019; **285**: 510–23.
593 doi:10.1111/joim.12876
- 594 33. Vaheri A, Henttonen H, Mustonen J. Hantavirus research in finland: Highlights and
595 perspectives. *Viruses* 2021; **13**: 1452. doi:10.3390/v13081452
- 596 34. Jiang H, Du H, Wang LM, Wang PZ, Bai XF. Hemorrhagic Fever with Renal
597 Syndrome: Pathogenesis and Clinical Picture. *Front Cell Infect Microbiol* 2016; **6**: 1.
598 doi:10.3389/fcimb.2016.00178
- 599 35. Liu R, Ma H, Shu J, Zhang Q, Han M, Liu Z, et al. Vaccines and Therapeutics Against
600 Hantaviruses. *Front Microbiol* 2020; **10**. doi:10.3389/fmicb.2019.02989
- 601 36. Terajima M, Ennis FA. T cells and pathogenesis of hantavirus cardiopulmonary
602 syndrome and hemorrhagic fever with renal syndrome. *Viruses* 2011; **3**: 1059–73.
603 doi:10.3390/v3071059
- 604 37. Sadeghi M, Eckerle I, Daniel V, Burkhardt U, Opelz G, Schnitzler P. Cytokine

- 605 expression during early and late phase of acute Puumala hantavirus infection. *BMC*
606 *Immunol* 2011; **12**. doi:10.1186/1471-2172-12-65
- 607 38. Linderholm M, Ahlm C, Settergren B, Waage A, Tärnvik A. Elevated plasma levels of
608 tumor necrosis factor (TNF)- α , soluble TNF receptors, interleukin (IL)-6, and IL-10 in
609 patients with hemorrhagic fever with renal syndrome. *J Infect Dis* 1996; **173**: 38–43.
610 doi:10.1093/infdis/173.1.38
- 611 39. Borges AA, Campos GM, Moreli ML, Moro Souza RL, Saggiaro FP, Figueiredo GG,
612 et al. Role of mixed Th1 and Th2 serum cytokines on pathogenesis and prognosis of
613 hantavirus pulmonary syndrome. *Microbes Infect* 2008; **10**: 1150–7.
614 doi:10.1016/j.micinf.2008.06.006
- 615 40. Saksida A, Wraber B, Avšič-Županc T. Serum levels of inflammatory and regulatory
616 cytokines in patients with hemorrhagic fever with renal syndrome. *BMC Infect Dis*
617 2011; **11**. doi:10.1186/1471-2334-11-142
- 618 41. Morzunov SP, Khaiboullina SF, St Jeor S, Rizvanov AA, Lombardi VC. Multiplex
619 Analysis of Serum Cytokines in Humans with Hantavirus Pulmonary Syndrome. *Front*
620 *Immunol* 2015; **6**: 432. doi:10.3389/fimmu.2015.00432
- 621 42. Maleki KT, Tauriainen J, García M, Kerkman PF, Christ W, Dias J, et al. MAIT cell
622 activation is associated with disease severity markers in acute hantavirus infection. *Cell*
623 *Reports Med* 2021; **2**: 100220. doi:10.1016/j.xcrm.2021.100220
- 624 43. Maleki KT, García M, Iglesias A, Alonso D, Ciancaglini M, Hammar U, et al. Serum
625 Markers Associated with Severity and Outcome of Hantavirus Pulmonary Syndrome. *J*
626 *Infect Dis* 2019; **219**: 1832–40. doi:10.1093/infdis/jiz005
- 627 44. Srikiatkachorn A, Spiropoulou CF. Vascular events in viral hemorrhagic fevers: A
628 comparative study of dengue and hantaviruses. *Cell Tissue Res* 2014; **355**: 621–33.
629 doi:10.1007/s00441-014-1841-9

- 630 45. Hepojoki J, Vaheri A, Strandin T. The fundamental role of endothelial cells in
631 hantavirus pathogenesis. *Front Microbiol* 2014; **5**: 1–7. doi:10.3389/fmicb.2014.00727
- 632 46. Linderholm M, Bjermer L, Juto P, Roos G, Sandström T, Settergren B, et al. Local host
633 response in the lower respiratory tract in nephropathia epidemica. *Scand J Infect Dis*
634 1993; **25**: 639–46. doi:10.3109/00365549309008554
- 635 47. Björkström NK, Lindgren T, Stoltz M, Fauriat C, Braun M, Evander M, et al. Rapid
636 expansion and long-term persistence of elevated NK cell numbers in humans infected
637 with hantavirus. *J Exp Med* 2011; **208**: 13–21. doi:10.1084/jem.20100762
- 638 48. Resman Rus K, Kopitar AN, Korva M, Ihan A, Petrovec M, Avšič-Županc T.
639 Comparison of Lymphocyte Populations in Patients With Dobrava or Puumala
640 orthohantavirus Infection. *Front Cell Infect Microbiol* 2020; **10**: 566149.
641 doi:10.3389/fcimb.2020.566149
- 642 49. Vietzen H, Hartenberger S, Aberle SW, Puchhammer-Stöckl E. Dissection of the
643 NKG2C NK cell response against Puumala Orthohantavirus. Holbrook MR, editor.
644 *PLoS Negl Trop Dis* 2021; **15**: e0010006. doi:10.1371/JOURNAL.PNTD.0010006
- 645 50. García M, Iglesias A, Landoni VI, Bellomo C, Bruno A, Córdoba MT, et al. Massive
646 plasmablast response elicited in the acute phase of hantavirus pulmonary syndrome.
647 *Immunology* 2017; **151**: 122–35. doi:10.1111/imm.12713
- 648 51. Rasmuson J, Pourazar J, Mohamed N, Lejon K, Evander M, Blomberg A, et al.
649 Cytotoxic immune responses in the lungs correlate to disease severity in patients with
650 hantavirus infection. *Eur J Clin Microbiol Infect Dis* 2016; **35**: 713–21.
651 doi:10.1007/s10096-016-2592-1
- 652 52. Iglesias AA, Períolo N, Bellomo CM, Lewis LC, Olivera CP, Anselmo CR, et al.
653 Delayed viral clearance despite high number of activated T cells during the acute phase
654 in Argentinean patients with hantavirus pulmonary syndrome. *eBioMedicine* 2022; **75**:

- 655 103765. doi:10.1016/j.ebiom.2021.103765
- 656 53. Kerkman PF, Dernstedt A, Tadala L, Mittler E, Dannborg M, Sundling C, et al.
657 Generation of plasma cells and CD27–IgD– B cells during hantavirus infection is
658 associated with distinct pathological findings. *Clin Transl Immunol* 2021; **10**: e1313.
659 doi:10.1002/cti2.1313
- 660 54. Hepojoki J, Cabrera LE, Hepojoki S, Bellomo C, Kareinen L, Andersson LC, et al.
661 Hantavirus infection-induced B cell activation elevates free light chains levels in
662 circulation. *PLoS Pathog* 2021; **17**. doi:10.1371/journal.ppat.1009843
- 663 55. Koma T, Yoshimatsu K, Nagata N, Sato Y, Shimizu K, Yasuda SP, et al. Neutrophil
664 Depletion Suppresses Pulmonary Vascular Hyperpermeability and Occurrence of
665 Pulmonary Edema Caused by Hantavirus Infection in C.B-17 SCID Mice. *J Virol*
666 2014; **88**: 7178–88. doi:10.1128/JVI.00254-14
- 667 56. Raftery MJ, Lalwani P, Krautkrämer E, Peters T, Scharffetter-Kochanek K, Krüger R,
668 et al. β 2 integrin mediates hantavirus-induced release of neutrophil extracellular traps.
669 *J Exp Med* 2014; **211**: 1485–97. doi:10.1084/jem.20131092
- 670 57. Strandin T, Mäkelä S, Mustonen J, Vaheri A. Neutrophil Activation in Acute
671 Hemorrhagic Fever With Renal Syndrome Is Mediated by Hantavirus-Infected
672 Microvascular Endothelial Cells. *Front Immunol* 2018; **9**: 2098.
673 doi:10.3389/fimmu.2018.02098
- 674 58. Marsac D, García S, Fournet A, Aguirre A, Pino K, Ferres M, et al. Infection of human
675 monocyte-derived dendritic cells by ANDES Hantavirus enhances pro-inflammatory
676 state, the secretion of active MMP-9 and indirectly enhances endothelial permeability.
677 *Virol J* 2011; **8**. doi:10.1186/1743-422X-8-223
- 678 59. Scholz S, Baharom F, Rankin G, Maleki KT, Gupta S, Vangeti S, et al. Human
679 hantavirus infection elicits pronounced redistribution of mononuclear phagocytes in

- 680 peripheral blood and airways. *PLoS Pathog* 2017; **13**.
- 681 doi:10.1371/journal.ppat.1006462
- 682 60. Raftery MJ, Lalwani P, Lütteke N, Kobak L, Giese T, Ulrich RG, et al. Replication in
683 the Mononuclear Phagocyte System (MPS) as a Determinant of Hantavirus
684 Pathogenicity. *Front Cell Infect Microbiol* 2020; **10**: 281.
685 doi:10.3389/fcimb.2020.00281
- 686 61. Vangeti S, Strandin T, Liu S, Tauriainen J, Räisänen-Sokolowski A, Cabrerai L, et al.
687 Monocyte subset redistribution from blood to kidneys in patients with Puumala virus
688 caused hemorrhagic fever with renal syndrome. *PLoS Pathog* 2021; **17**.
689 doi:10.1371/journal.ppat.1009400
- 690 62. Cabrera LE, Schmotz C, Saleem MA, Lehtonen S, Vapalahti O, Vaheri A, et al.
691 Increased Heparanase Levels in Urine during Acute Puumala Orthohantavirus Infection
692 Are Associated with Disease Severity. *Viruses* 2022; **14**: 450. doi:10.3390/v14030450
- 693 63. Niskanen S, Jääskeläinen A, Vapalahti O, Sironen T. Evaluation of real-time RT-PCR
694 for diagnostic use in detection of puumala virus. *Viruses* 2019; **11**.
695 doi:10.3390/v11070661
- 696 64. Kyriakidis I, Papa A. Serum TNF- α , sTNFR1, IL-6, IL-8 and IL-10 levels in
697 hemorrhagic fever with renal syndrome. *Virus Res* 2013; **175**: 91–4.
698 doi:10.1016/j.virusres.2013.03.020
- 699 65. Khaiboullina SF, Levis S, Morzunov SP, Martynova E V., Anokhin VA, Gusev OA, et
700 al. Serum cytokine profiles differentiating hemorrhagic fever with renal syndrome and
701 hantavirus pulmonary syndrome. *Front Immunol* 2017; **8**.
702 doi:10.3389/fimmu.2017.00567
- 703 66. Angulo J, Martínez-Valdebenito C, Marco C, Galeno H, Villagra E, Vera L, et al.
704 Serum levels of interleukin-6 are linked to the severity of the disease caused by Andes

- 705 Virus. *PLoS Negl Trop Dis* 2017; **11**: e0005757. doi:10.1371/journal.pntd.0005757
- 706 67. Guo J, Guo X, Wang Y, Tian F, Luo W, Zou Y. Cytokine response to Hantaan virus
707 infection in patients with hemorrhagic fever with renal syndrome. *J Med Virol* 2017;
708 **89**: 1139–45. doi:10.1002/jmv.24752
- 709 68. Walker JA, McKenzie ANJ. TH2 cell development and function. *Nat Rev Immunol*
710 2018; **18**: 121–33. doi:10.1038/nri.2017.118
- 711 69. Kato A. Group 2 Innate Lymphoid Cells in Airway Diseases. *Chest* 2019; **156**: 141–9.
712 doi:10.1016/j.chest.2019.04.101
- 713 70. Ngo VL, Abo H, Maxim E, Harusato A, Geem D, Medina-Contreras O, et al. A
714 cytokine network involving IL-36 γ , IL-23, and IL-22 promotes antimicrobial defense
715 and recovery from intestinal barrier damage. *Proc Natl Acad Sci U S A* 2018; **115**:
716 E5076–85. doi:10.1073/pnas.1718902115
- 717 71. Yudanin NA, Schmitz F, Flamar AL, Thome JJC, Tait Wojno E, Moeller JB, et al.
718 Spatial and Temporal Mapping of Human Innate Lymphoid Cells Reveals Elements of
719 Tissue Specificity. *Immunity* 2019; **50**: 505-519.e4. doi:10.1016/j.immuni.2019.01.012
- 720 72. Gupta S, Braun M, Tischler ND, Stoltz M, Sundström KB, Björkström NK, et al.
721 Hantavirus-infection Confers Resistance to Cytotoxic Lymphocyte-Mediated
722 Apoptosis. Heise MT, editor. *PLoS Pathog* 2013; **9**: e1003272.
723 doi:10.1371/journal.ppat.1003272
- 724 73. Braun M, Björkström NK, Gupta S, Sundström K, Ahlm C, Klingström J, et al. NK
725 Cell Activation in Human Hantavirus Infection Explained by Virus-Induced IL-
726 15/IL15R α Expression. Basler CF, editor. *PLoS Pathog* 2014; **10**: e1004521.
727 doi:10.1371/journal.ppat.1004521
- 728 74. Dhariwal J, Cameron A, Wong E, Paulsen M, Trujillo-Torrallbo MB, Del Rosario A, et
729 al. Pulmonary innate lymphoid cell responses during rhinovirus-induced asthma

- 730 exacerbations in vivo: A clinical trial. *Am J Respir Crit Care Med* 2021; **204**: 1259–73.
731 doi:10.1164/rccm.202010-3754OC
- 732 75. Khaiboullina SF, Martynova E V, Khamidullina ZL, Lapteva E V, Nikolaeva I V,
733 Anokhin V V, et al. Upregulation of IFN- γ and IL-12 is associated with a milder form
734 of hantavirus hemorrhagic fever with renal syndrome. *Eur J Clin Microbiol Infect Dis*
735 2014; **33**: 2149–56. doi:10.1007/s10096-014-2176-x
- 736 76. Peters CJ, Simpson GL, Levy H. Spectrum of hantavirus infection: hemorrhagic fever
737 with renal syndrome and hantavirus pulmonary syndrome. *Annu Rev Med* 1999; **50**:
738 531–45. doi:10.1146/annurev.med.50.1.531
- 739 77. Mustonen J, Mäkelä S, Outinen T, Laine O, Jylhävä J, Arstila PT, et al. The
740 pathogenesis of nephropathia epidemica: New knowledge and unanswered questions.
741 *Antiviral Res* 2013; **100**: 589–604. doi:10.1016/j.antiviral.2013.10.001
- 742 78. Jiang H, Zheng X, Wang L, Du H, Wang P, Bai X. Hantavirus infection: a global
743 zoonotic challenge. *Virol Sin* 2017; **32**: 32–43. doi:10.1007/s12250-016-3899-x
- 744 79. Korva M, Saksida A, Kejžar N, Schmaljohn C, Avšič-Županc T. Viral load and
745 immune response dynamics in patients with haemorrhagic fever with renal syndrome.
746 *Clin Microbiol Infect* 2013; **19**: E358–66. doi:10.1111/1469-0691.12218
- 747 80. Pettersson L, Thunberg T, Rocklöv J, Klingström J, Evander M, Ahlm C. Viral load
748 and humoral immune response in association with disease severity in Puumala
749 hantavirus-infected patients-implications for treatment. *Clin Microbiol Infect* 2014; **20**:
750 235–41. doi:10.1111/1469-0691.12259
- 751 81. Mjösberg JM, Trifari S, Crellin NK, Peters CP, Van Drunen CM, Piet B, et al. Human
752 IL-25-and IL-33-responsive type 2 innate lymphoid cells are defined by expression of
753 CRTH2 and CD161. *Nat Immunol* 2011; **12**: 1055–62. doi:10.1038/ni.2104
- 754 82. Mindt BC, Fritz JH, Duerr CU. Group 2 innate lymphoid cells in pulmonary immunity

- 755 and tissue homeostasis. *Front Immunol* 2018; **9**: 1. doi:10.3389/fimmu.2018.00840
- 756 83. Fonseca W, Lukacs NW, Elesela S, Malinczak CA. Role of ILC2 in Viral-Induced
757 Lung Pathogenesis. *Front Immunol* 2021; **12**. doi:10.3389/fimmu.2021.675169
- 758 84. Rodriguez-Rodriguez N, Gogoi M, McKenzie ANJ. Group 2 Innate Lymphoid Cells:
759 Team Players in Regulating Asthma. *Annu Rev Immunol* 2021; **39**: 167–98.
760 doi:10.1146/annurev-immunol-110119-091711
- 761 85. Zhang Y, Zhang C, Zhuang R, Ma Y, Zhang Y, Yi J, et al. IL-33/ST2 Correlates with
762 Severity of Haemorrhagic Fever with Renal Syndrome and Regulates the Inflammatory
763 Response in Hantaan Virus-Infected Endothelial Cells. *PLoS Negl Trop Dis* 2015; **9**.
764 doi:10.1371/journal.pntd.0003514
- 765 86. Habtezion A, Nguyen LP, Hadeiba H, Butcher EC. Leukocyte Trafficking to the Small
766 Intestine and Colon. *Gastroenterology* 2016; **150**: 340–54.
767 doi:10.1053/j.gastro.2015.10.046
- 768 87. Lee M, Kiefel H, Lajevic MD, Macauley MS, O’Hara E, Pan J, et al. Transcriptional
769 programs of lymphoid tissue capillary and high endothelium reveal control
770 mechanisms for lymphocyte homing. *Nat Immunol* 2014; **15**: 982. doi:10.1038/NI.2983
- 771 88. Ito T, Carson WF, Cavassani KA, Connett JM, Kunkel SL. CCR6 as a mediator of
772 immunity in the lung and gut. *Exp Cell Res* 2011; **317**: 613–9.
773 doi:10.1016/j.yexcr.2010.12.018
- 774 89. Bargatze RF, Jutila MA, Butcher EC. Distinct roles of L-selectin and integrins $\alpha 4\beta 7$
775 and LFA-1 in lymphocyte homing to Peyer’s patch-HEV in situ: The multistep model
776 confirmed and refined. *Immunity* 1995; **3**: 99–108. doi:10.1016/1074-7613(95)90162-0
- 777 90. Solà-Riera C, Gupta S, Maleki KT, González-Rodríguez P, Saidi D, Zimmer CL, et al.
778 Hantavirus Inhibits TRAIL-Mediated Killing of Infected Cells by Downregulating
779 Death Receptor 5. *Cell Rep* 2019; **28**: 2124–2139.e6. doi:10.1016/j.celrep.2019.07.066

- 780 91. Solà-Riera C, García M, Ljunggren HG, Klingström J. Hantavirus inhibits apoptosis by
781 preventing mitochondrial membrane potential loss through up-regulation of the pro-
782 survival factor BCL-2. *PLoS Pathog* 2020; **16**: e1008297.
783 doi:10.1371/journal.ppat.1008297
- 784 92. Katze MG, He Y, Gale M. Viruses and interferon: A fight for supremacy. *Nat Rev*
785 *Immunol* 2002; **2**: 675–87. doi:10.1038/nri888
- 786 93. Samuel CE. Antiviral actions of interferons. *Clin Microbiol Rev* 2001; **14**: 778–809.
787 doi:10.1128/CMR.14.4.778-809.2001
- 788 94. Kang S, Brown HM, Hwang S. Direct antiviral mechanisms of interferon-gamma.
789 *Immune Netw* 2018; **18**. doi:10.4110/in.2018.18.e33
- 790 95. Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN- γ): Exploring its implications in
791 infectious diseases. *Biomol Concepts* 2018; **9**: 64–79. doi:10.1515/bmc-2018-0007
- 792 96. Kurioka A, Cosgrove C, Simoni Y, van Wilgenburg B, Geremia A, Björkander S, et al.
793 CD161 defines a functionally distinct subset of pro-inflammatory natural killer cells.
794 *Front Immunol* 2018; **9**: 486. doi:10.3389/fimmu.2018.00486
- 795 97. Alter G, Jost S, Rihn S, Reyor LL, Nolan BE, Ghebremichael M, et al. Reduced
796 frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV
797 infection may predict viral clearance. *J Hepatol* 2011; **55**: 278–88.
798 doi:10.1016/j.jhep.2010.11.030
- 799 98. Petitdemange C, Becquart P, Wauquier N, Béziat V, Debré P, Leroy EM, et al.
800 Unconventional repertoire profile is imprinted during acute chikungunya infection for
801 natural killer cells polarization toward cytotoxicity. *PLoS Pathog* 2011; **7**.
802 doi:10.1371/journal.ppat.1002268
- 803 99. Leeansyah E, Ganesh A, Quigley MF, Sönnnerborg A, Andersson J, Hunt PW, et al.
804 Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted

- 805 MAIT-cell population in chronic HIV-1 infection. *Blood* 2013; **121**: 1124–35.
806 doi:10.1182/blood-2012-07-445429
- 807 100. Wang Z, Guan D, Huo J, Biswas SK, Huang Y, Yang Y, et al. IL-10 Enhances Human
808 Natural Killer Cell Effector Functions via Metabolic Reprogramming Regulated by
809 mTORC1 Signaling. *Front Immunol* 2021; **12**: 366. doi:10.3389/fimmu.2021.619195
810

811 **FIGURE LEGENDS**

812 **1. Cohort design and clinical characterization of PUUV-infected hemorrhagic fever with**
813 **renal syndrome (HFRS) patients.**

814 **(a)** Schematic overview of peripheral blood sample collection in control subjects (n=10) and
815 PUUV-infected HFRS patients (n=17) at acute (5 to 8 days), early convalescence (20 to 27
816 days), and late convalescence phase (180- or 360-days post onset of symptoms).

817 **(b)** Levels of platelets ($10^9/L$), creatinine ($\mu\text{mol/L}$), C-reactive protein (CRP, mg/L), and copy
818 numbers of PUUV S RNA in plasma ($10^4/\text{ml}$) in acute (n=14), early convalescence (n=15),
819 and late convalescence (n=17) phase. Dotted lines indicate reference values in healthy adults.

820 Graphs show data of individual subjects (circles) and the median (bars) \pm interquartile
821 range. Statistical significance was assessed using the Wilcoxon signed-rank test. Severe
822 patients are indicated by a black circle. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$.

823

824 **2. Altered levels of soluble factors in peripheral blood of HFRS patients.**

825 **(a)** Heatmap displaying the normalized plasma concentration of each soluble factor in each
826 HFRS patient at acute, early convalescent, and late convalescent phase, as measured by
827 multiplex immunoassay. Colors depict high (red) or low (blue) concentration. Values were
828 normalized dividing each one by the highest value obtained for the given soluble factor.

829 **(b)** Level of soluble factors in plasma of HFRS patients in acute (n=15), early convalescence
830 (n=16), and late convalescence (n=17) phase.

831 **(c)** Principal component analysis (PCA) displaying the distribution of HFRS patients
832 according to the plasma level of soluble factors.

833 **(d-f)** Spearman rank correlation between plasma levels of **(d)** IL-25 and IL-13, **(e)** IL-25 and
834 TSLP, and **(f)** IFN- γ and viral load in acute HFRS patients (n=15).

835 Abbreviations: IFN- γ : interferon gamma; IL: interleukin; TNF: tumor necrosis factor
836 alpha; TSLP: Thymic stromal lymphopoietin; GM-CSF: granulocyte-macrophage colony-
837 stimulating factor; CCL: chemokine ligand. Graphs show data of individual subjects (circles)
838 and the median (bars) \pm interquartile range. Statistical significance was assessed using the
839 Wilcoxon signed-rank test. Severe patients are indicated by a black circle and patient 3 is
840 labeled as P03. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$.

841

842 **3. NK cells are activated, proliferative and decreased in frequency in peripheral blood of**
843 **HFRS patients.**

844 **(a)** Percentage of NK cells out of CD45⁺ lymphocytes (Ly) in control donors (n=10) and
845 HFRS patients during the acute (n=15), early convalescence (n=16), and late convalescence
846 (n=17) phase.

847 **(b)** Representative flow cytometry plots showing percentage of CD56^{bright} and CD56^{dim} NK
848 cells (gated as CD3⁺CD56⁺ cells as in Fig S2) in a control donor and in an HFRS patient. **(c)**
849 Percentage of CD56^{bright} and CD56^{dim} NK cells of CD3⁺CD56⁺ cells in control donors (n=10)
850 and HFRS patients during the acute (n=15), early convalescence (n=16), and late
851 convalescence (n=17) phase.

852 **(d)** Percentage of CD69⁺, Ki-67⁺, HLA-DR⁺, NKp44⁺, NKG2A⁺, CCR6⁺, CCR10⁺, α 4 β 7⁺,
853 CD45RA⁺, and CD161⁺ NK cells of total CD3⁺CD56⁺ cells in control donors (n=10) and
854 HFRS patients during the acute (n=15), early convalescence (n=16), and late convalescence
855 (n=17) phase.

856 **(e)** Principal component analysis (PCA) of total CD3⁺CD56⁺ NK cells in healthy controls and
857 HFRS patients displaying the contribution of NK cell surface markers indicated in **(d)**. Each
858 dot represents one donor.

859 **(f-k)** Spearman rank correlation between plasma IL-10 levels and the percentage of **(f)** CD69⁺
860 NK cells and **g.** Ki-67⁺ NK cells, between plasma granzyme A (GrzA) levels and the
861 percentage of **(h)** CD69⁺ NK cells and **(i)** CD161⁺ NK cells, and between plasma viral load
862 (n=13; PUUV S RNA copies/mL) and the percentage of **(j)** NK cells out of CD45⁺
863 lymphocytes and **(k)** CD69⁺ NK cells in acute HFRS patients.

864 Bar graphs are shown as mean and lines connect paired samples from the same
865 patient. Statistical significance was assessed using the Wilcoxon signed-rank test to compare
866 groups of HFRS patients, and the Kruskal-Wallis test followed by Dunn's multiple
867 comparisons test to compare healthy controls with groups of HFRS patients. Severe patients
868 are indicated by black circles. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

869

870 **4. ILCs display an activated and proliferative profile in peripheral blood of HFRS** 871 **patients.**

872 **(a)** Percentage of ILCs (gated as Lin⁻CD3⁻CD127^{hi} as in Fig S2) out of CD45⁺ lymphocytes
873 (Ly) in control donors (n=10) and HFRS patients during the acute (n=15), early
874 convalescence (n=16), and late convalescent (n=17) phase.

875 **(b)** Spearman rank correlation between plasma viral load (PUUV S RNA copies/mL) and the
876 percentage of ILCs out of CD45⁺ lymphocytes in acute HFRS patients (n=15).

877 **(c)** Representative flow cytometry plots showing percentage of ILC2 and naïve ILC (nILC) in
878 a control donor and in an HFRS patient (gated on ILCs as in Fig S2). **(d)** Percentage of ILC2
879 and nILC in control donors (n=10) and HFRS patients during the acute (n=15), early
880 convalescence (n=16), and late convalescence (n=17) phase.

881 **(e)** Percentage of CD69⁺, Ki-67⁺, HLA-DR⁺, NKp44⁺, CD56⁺, CCR6⁺, CCR10⁺, α4β7⁺, and
882 CD45RA⁺ nILC in control donors (n=10) and HFRS patients during the acute (n=15), early
883 convalescence (n=16), and late convalescence (n=17) phase. **(f)** Principal component analysis

884 (PCA) of nILC in control donors and HFRS patients displaying the contribution of nILC
885 surface markers indicated in (e). (g) Percentage of CD69⁺, Ki-67⁺, HLA-DR⁺, NKp44⁺,
886 CD56⁺, CCR6⁺, CCR10⁺, $\alpha 4\beta 7$ ⁺, and CD45RA⁺ ILC2 in control donors (n=10) and HFRS
887 patients during the acute (n=15), early convalescence (n=16), and late convalescence (n=17)
888 phase. (h) PCA of ILC2 in control donors and HFRS patients displaying the contribution of
889 ILC2 surface markers indicated in (g). (i-k) Spearman rank correlation between (i) plasma IL-
890 10 levels and the percentage of CD69⁺ ILC2, (j) plasma CCL27 levels and the percentage of
891 CCR10⁺ ILC2, and (k) plasma TSLP levels and the percentage of CCR10⁺ ILC2 in acute
892 HFRS patients (n=15).

893 Bar graphs are shown as mean and lines connect paired samples from the same
894 patient. Statistical significance was assessed using the Wilcoxon signed-rank test to compare
895 groups of HFRS patients, and the Kruskal-Wallis test followed by Dunn's multiple
896 comparisons test to compare healthy controls with groups of HFRS patients. Severe patients
897 are indicated by a black circle. Patients with low cell numbers (fewer than 20 events) in the
898 corresponding gate were removed from the analysis. *p < 0.05; **p < 0.01; ***p < 0.001;
899 ****p < 0.0001.

900

901 **5. Increased ILC2 c-Kit^{lo} frequency in peripheral blood of acute HFRS patients.**

902 (a) Representative flow cytometry plots showing percentages of c-Kit^{lo} and c-Kit^{hi} ILC2 in a
903 control donor and in an HFRS patient (gated on total ILC2 as in Fig S2). (b) Percentage of c-
904 Kit^{lo} and c-Kit^{hi} ILC2 in control donors (n=10) and HFRS patients during the acute (n=15),
905 early convalescence (n=16), and late convalescence (n=17) phase. (c) Percentage of CCR6⁺ c-
906 Kit^{lo} and CCR6⁺ c-Kit^{hi} ILC2 in control donors (n=10) and HFRS patients during the acute
907 (n=15), early convalescence (n=16), and late convalescence (n=17) phase.

908 Bar graphs are shown as mean and lines connect paired samples from the same
909 patient. Statistical significance was assessed using the Wilcoxon signed-rank test to compare
910 groups of HFRS patients, and the Kruskal-Wallis test followed by Dunn's multiple
911 comparisons test to compare healthy controls with groups of HFRS patients. Severe patients
912 are indicated by a black circle. Patients with low cell numbers (fewer than 20 events) in the
913 corresponding gate were removed from the analysis. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

Table 1. Clinical and laboratory characteristics of donors.

Characteristic	HFRS patients	Healthy controls
n° of patients / controls	17	10
Age (years), median (IQR)	35(28.5-51)	47.5 (38.25-53.25)
Gender (female), n° (%)	12 (71)	2 (20)
Viral load at time of sampling (PUUV S RNA copies/mL), median (IQR)	94,272 (47,300-187,975)	ND
Platelet count ($\times 10^9/L$), median (IQR)	97 (85-119)	ND
CRP (mg/L), median (IQR)	58.2 (33.4-93.5)	ND
Creatinine ($\mu\text{mol/L}$), median (IQR)	146 (96-298)	ND
Days after symptoms onset, median (IQR)	6 (6-8)	NA
Days hospitalized, median (IQR)	5 (4 - 6.5)	NA
Hematocrit (L/L) median (IQR)	0.37 (0.37-0.41)	ND
PCR positivity CMV, n° (%)	0 (0)	ND
PCR positivity EBV, n° (%)	1 (6)	ND

NA: not applicable; ND: not determined; IQR: interquartile range; CRP: C-reactive protein;
CMV: cytomegalovirus; EBV: Epstein-Barr virus

Platelet count; normal range 150–360 $\times 10^9/L$.

Plasma CRP; reference <3 mg/L.

Plasma creatinine; reference <90 $\mu\text{mol/L}$ for women, <100 $\mu\text{mol/L}$ for men.

Figure 1




Figure 2




Figure 3




Figure 4






Figure 5

a



b



c

